Vivus and Auxilium's Stendra ED drug approved as 'on-demand' treatment in USA
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Stendra (avanafil), developed by Vivus (Nasdaq: VVUS) and marketed in the USA and Canada by Auxilium Pharmaceuticals (Nasdaq: AUXL).
Stendra, a prescription drug cleared for EC in 2012, is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as around 15 minutes before sexual activity. Vivus’ shares rose 12.9% to $4.38 in morning trading Thursday following the news.
Stendra is available in multiple dosage strengths (50mg, 100mg and 200mg tablets) and may be taken with or without food and moderate alcohol consumption (up to three drinks). In clinical studies, when compared to placebo, Stendra A helped more men achieve an erection in as early as about 15 minutes that lasted long enough to successfully complete sexual intercourse.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze